Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

G1 Therapeutics To Discontinue Phase 3 PRESERVE 1 Trial

Por: RTTNews Health February 13, 2023

thumbnail

Oncology company G1 Therapeutics, Inc. () announced Monday topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance.However, early anti-tumor efficacy data, including overall response rate (ORR) and preliminary measures of survival, favored the placebo arm. Other clinical trials of trilaciclib in combination with different... + full article



Similar News

How Derek Jeter’s arrival may leave Frank Thomas looking for a new spot in Fox’s MLB lineup

New York Post USA Sports February 27, 2023

thumbnailFrank Thomas’ future at Fox Sports is in limbo with the on the network’s biggest pre- and post-game Major League Baseball shows, The Post has learned. What you need to know: 1️⃣ The 54-year-old Thomas has been with Fox Sports since 2016. He is generally liked, but when... + más

Bob Raissman: Fox gives Derek Jeter a spot landing spot for the next chapter of his baseball career | New York Daily News

Derek Jeter’s Foray Into Sports Team Ownership Appears To Be A One And Done Experiment | Forbes


Rhea Ripley Wins 2023 Royal Rumble; Faces Bianca Belair or Charlotte at WrestleMania

Bleacher Report USA Sports January 29, 2023

thumbnailRhea Ripley won the sixth annual women's Royal Rumble match at the same-titled pay-per-view on Saturday night, guaranteeing her a shot at the Raw or SmackDown Women's Championship at WrestleMania 39.Entering from the No. 1 spot, The Eradiacator beat out 29 of the top... + más

WWE Royal Rumble 2023 Results: Rhea Ripley Wins Women’s Royal Rumble At No. 1 | Forbes

WWE WrestleMania 39: Roman Reigns Vs. Cody Rhodes And The 5 Most Likely Main Events | Forbes


Can ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta?

RTTNews USA Health January 18, 2023

thumbnailThis commercial-stage biotechnology company developing next-generation, targeted antibody drug conjugates is aiming to achieve double-digit year-over-year revenue growth for its lead drug.The company we are profiling today is ADC Therapeutics SA () and the drug in focus is... + más

Nkarta | RTTNews

Chicago White Sox pitcher Liam Hendriks says he will undergo cancer treatment after being diagnosed with non-Hodgkin's lymphoma | CBS News


No. 25 Ohio State's Game-Winning 3 vs. Rutgers Shouldn't Have Counted, Big Ten Says

Bleacher Report USA Sports December 10, 2022

thumbnailThe No. 25 Ohio State Buckeyes defeated the unranked Rutgers Scarlet Knights 67-66 on Thursday night on a three-point buzzer-beater by Tanner Holden.However, the Big Ten announced Friday that Holden's three-pointer shouldn't have counted, per NCAA.com's .The Big... + más

Stringer honored, No. 4 Ohio State women beat Rutgers 82-70 | 10 WBNS

Rutgers dismisses offensive coordinator Gleeson | ESPN


Pills could replace daily injections in the near future

WPTV USA Nation November 30, 2022

thumbnailIf you or someone you love deals with a chronic disease, you're likely aware of injections. New research is indicating that in the not-too-distant future, that same medication and routine vaccinations might come in a pill form.For 10 years, biotech company has been working... + más

Op-Ed: Fentanyl pill producers used to mimic other pharmaceuticals, now they don't have to | Los Angeles Times

Hey FDA, Free the Birth Control Pill! | The Daily Beast


Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China

RTTNews USA Health November 29, 2022

thumbnailBiopharmaceutical company Aclaris Therapeutics, Inc. () and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop,... + más

Visconti: Pens And Inks For Fall | Forbes

Subscribe to HP Instant Ink and save $100s per year on ink | New York Post


Boston startup Ascidian Therapeutics charts vision for therapies that ‘rewrite RNA’

The Boston Globe USA Business October 12, 2022

thumbnailCompetition is heating up among biotech startups building technologies that improve or expand upon what gene editing can do. While most of these firms are devising therapies that permanently modify DNA to treat, and potentially cure, genetic diseases, a growing number think that... + más

Tech insiders have a lot to say about the local startup scene. Most of it is good. | The Boston Globe

See the presentations that hot healthcare startups used to raise millions from top VCs | Business Insider



About iurex | Privacy Policy | Disclaimer |